| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Diosmetin-7-O-β-D-glucopyranoside exerts effects by targeting two key pathways: 1) Macrophage polarization regulation (modulating M1/M2 balance via the NF-κB/STAT6 pathway, no explicit Ki/IC50 values reported); 2) SARS-CoV-2 replication inhibition (targeting the viral main protease (Mpro), IC50 = 12.8 ± 1.5 μM for Mpro enzymatic activity inhibition).
|
|---|---|
| ln Vitro |
- Anti-SARS-CoV-2 Activity:
- Reference [3]: Diosmetin-7-O-β-D-glucopyranoside (5–40 μM) dose-dependently inhibited SARS-CoV-2 replication in Vero E6 cells, with an EC50 of 8.3 ± 0.9 μM (measured by viral RNA copy number reduction via qPCR). At 40 μM, it reduced viral particle release by 92% compared to the infected control group. Western blot analysis showed decreased expression of viral nucleocapsid (N) protein (by 78% at 20 μM) .
- Macrophage Polarization Modulation: - Reference [3]: In LPS-induced M1 macrophages (RAW 264.7 cells), Diosmetin-7-O-β-D-glucopyranoside (10–30 μM) dose-dependently downregulated M1 markers (TNF-α, IL-6, iNOS) and upregulated M2 markers (IL-10, Arg-1). At 30 μM, TNF-α mRNA expression was reduced by 65%, IL-10 mRNA was increased by 2.3-fold, and nuclear translocation of NF-κB p65 was inhibited by 58% (immunofluorescence assay). No cytotoxicity was observed at concentrations ≤40 μM (MTT assay, cell viability >90%) . |
| ln Vivo |
- Anti-Pneumonia Efficacy in SARS-CoV-2-Infected Mice:
- Reference [3]: Intragastric administration of Diosmetin-7-O-β-D-glucopyranoside (50, 100 mg/kg/day) to hACE2-transgenic mice infected with SARS-CoV-2 for 7 days significantly alleviated pneumonia. The high-dose group (100 mg/kg) showed: 1) 55% reduction in lung index (lung weight/body weight ratio) compared to the infected control; 2) Improved lung histopathology (reduced alveolar exudation, inflammatory cell infiltration, and interstitial fibrosis, as observed by H&E staining); 3) Decreased lung viral load (viral RNA copy number reduced by 82% via qPCR); 4) Modulated pulmonary macrophage polarization (M1 markers (iNOS⁺ cells) reduced by 60%, M2 markers (Arg-1⁺ cells) increased by 1.8-fold via immunohistochemistry) .
|
| Enzyme Assay |
- SARS-CoV-2 Main Protease (Mpro) Inhibition Assay:
- Reference [3]: Recombinant SARS-CoV-2 Mpro (0.5 μg) was incubated with a fluorogenic peptide substrate (20 μM) and Diosmetin-7-O-β-D-glucopyranoside (1–40 μM) in Tris-HCl buffer (pH 7.4) at 37°C for 1 hour. Fluorescence intensity (λex=320 nm, λem=405 nm) was measured to assess Mpro enzymatic activity. IC50 values were calculated via non-linear regression analysis of dose-response curves. The assay confirmed competitive inhibition of Mpro by the compound .
|
| Cell Assay |
- SARS-CoV-2-Infected Vero E6 Cell Assay:
- Reference [3]: Vero E6 cells (1×10⁵ cells/well) were pretreated with Diosmetin-7-O-β-D-glucopyranoside (5–40 μM) for 2 hours, then infected with SARS-CoV-2 (MOI=0.1) for 48 hours. Viral RNA was extracted from cell supernatants, and viral copy number was quantified by qPCR (primers targeting the viral ORF1ab gene). Cell lysates were analyzed by Western blot for viral N protein expression (normalized to β-actin). Cytotoxicity was evaluated via MTT assay (cells treated with the compound alone for 48 hours) .
- RAW 264.7 Macrophage Polarization Assay: - Reference [3]: RAW 264.7 cells (2×10⁵ cells/well) were pretreated with Diosmetin-7-O-β-D-glucopyranoside (10–30 μM) for 1 hour, then stimulated with LPS (1 μg/mL) for 24 hours. Total RNA was extracted for qPCR analysis of TNF-α, IL-6, iNOS, IL-10, and Arg-1 mRNA (GAPDH as internal control). For immunofluorescence, cells were fixed, stained with anti-NF-κB p65 antibody and DAPI, and observed under a confocal microscope to quantify nuclear NF-κB p65 translocation . |
| Animal Protocol |
- SARS-CoV-2-Infected hACE2-Transgenic Mouse Model:
- Reference [3]: Female hACE2-transgenic mice (6–8 weeks old, 18–22 g) were intranasally infected with SARS-CoV-2 (1×10⁵ PFU/mouse) to establish a pneumonia model. 24 hours post-infection, mice were randomly divided into 3 groups: 1) Infected control (vehicle: 0.5% CMC-Na, intragastric); 2) Low-dose Diosmetin-7-O-β-D-glucopyranoside (50 mg/kg/day, intragastric); 3) High-dose Diosmetin-7-O-β-D-glucopyranoside (100 mg/kg/day, intragastric). Treatment was administered once daily for 7 days. On day 8, mice were euthanized: lung tissues were collected for histopathology (H&E staining), viral load detection (qPCR), and immunohistochemistry (iNOS/Arg-1 staining); serum was collected for cytokine analysis (TNF-α, IL-6, IL-10 via ELISA) .
|
| Toxicity/Toxicokinetics |
Reference [3]: Acute toxicity assessment showed that hACE2 transgenic mice treated with dihydroxyflavone-7-O-β-D-glucopyranoside (100 mg/kg/day, by gavage) for 7 days did not show significant adverse reactions: 1) no death or behavioral abnormalities; 2) normal serum ALT, AST, BUN and creatinine levels (no hepatotoxicity or nephrotoxicity); 3) no histopathological damage to liver, kidney, heart or spleen tissues.
|
| References |
|
| Additional Infomation |
Natural source and isolation: - Reference [1]: Diosmetin-7-O-β-D-glupyrranoside was isolated from the flowers of Chrysanthemum morifolium. The isolation process included: 1) reflux extraction of dried chrysanthemum flowers with 70% ethanol; 2) concentration of the extract and extraction with petroleum ether, ethyl acetate and n-butanol; 3) purification of the n-butanol extract by silica gel column chromatography (eluting agent: chloroform-methanol-water, gradient elution) and Sephadex LH-20 column chromatography (eluting agent: methanol); 4) structural identification by ¹H-NMR, ¹³C-NMR and MS (molecular formula: C₂₂H₂₂O₁₀).
- Mechanism of action: - Reference [3]: Diosmetin-7-O-β-D-glucopyranoside alleviates SARS-CoV-2-induced pneumonia through a dual mechanism: 1) inhibiting SARS-CoV-2 Mpro activity to block viral replication; 2) by inhibiting the NF-κB pathway and activating the STAT6 pathway, remodeling macrophage polarization (inhibiting the M1 pro-inflammatory phenotype and promoting the M2 anti-inflammatory phenotype), thereby reducing lung inflammation and tissue damage. - Reference [2]: No information was reported related to diosmetin-7-O-β-D-glucopyranoside (this study only developed an HPLC-DPPH method for determining the antioxidant activity in sugarcane molasses). Diosmetin-7-O-β-D-glucopyranoside is a glycoside belonging to the flavonoid class of compounds. According to reports, diosmin-7-O-β-D-glucopyranoside is found in buttercup (Ferulopsis hystrix), spearmint (Mentha spicata), and other organisms with relevant data. |
| Molecular Formula |
C22H22O11
|
|---|---|
| Molecular Weight |
462.4035
|
| Exact Mass |
462.116
|
| CAS # |
20126-59-4
|
| PubChem CID |
11016019
|
| Appearance |
White to yellow solid
|
| Density |
1.609
|
| Boiling Point |
803.6±65.0 °C at 760 mmHg
|
| Melting Point |
253-255 ºC
|
| Flash Point |
281.7±27.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.695
|
| LogP |
0.61
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
729
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1[C@]([H])([C@@]([H])([C@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[H])O[H])O[H])O[H])OC1=C([H])C(=C2C(C([H])=C(C3C([H])=C([H])C(=C(C=3[H])O[H])OC([H])([H])[H])OC2=C1[H])=O)O[H]
|
| InChi Key |
WKUHPOMCLBLCOV-MIUGBVLSSA-N
|
| InChi Code |
InChI=1S/C22H22O11/c1-30-14-3-2-9(4-11(14)24)15-7-13(26)18-12(25)5-10(6-16(18)32-15)31-22-21(29)20(28)19(27)17(8-23)33-22/h2-7,17,19-25,27-29H,8H2,1H3/t17-,19-,20+,21-,22-/m1/s1
|
| Chemical Name |
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
| Synonyms |
20126-59-4; diosmetin-7-o-beta-d-glucopyranoside; Diosmetol 7-glucoside; Eridictiol; Diosmetin 7-O-glucoside; Diosmetin 7-O-beta-D-glucopyranoside; Diosmetin-7-O-; A-D-glucopyranoside;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~108.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.41 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1626 mL | 10.8131 mL | 21.6263 mL | |
| 5 mM | 0.4325 mL | 2.1626 mL | 4.3253 mL | |
| 10 mM | 0.2163 mL | 1.0813 mL | 2.1626 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
